12.29 USD
▼-0.83-6.33%
盘后 12.20 -0.73%
2026-09-15
市值
$369.89M
市盈率
—
EPS
-2.34
股息率
—
52 周区间
7.05 – 17.15
成交量
284.88K
Beta
0.94
目标价
21.83
52W 低 7.0552W 高 17.15
价格走势
公司简介
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urtica...